Brought to you by 
RF pain device developer Relievant completes $30mm Series D financing
01 May 2012
Executive Summary
New Enterprise Associates has led a $30mm Series D round for Relievant Medsystems Inc. (radiofrequency nerve ablation devices). Returning shareholders Canaan Partners, Emergent Medical Partners, Morgenthaler Ventures, and Onset Ventures also joined. The funding will support Relievant’s recently initiated surgical multi-center assessment of RF ablation for the treatment of vertebrogenic back pain (SMART) trial, which will evaluate the Intracept system in chronic axial low back pain. The minimally invasive probe delivers radiofrequency ablation to prevent pain signals from being transmitted by the basivertebral nerve.
Deal Industry
- Medical Devices
-
Medical Devices
- Radiofrequency Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
RF pain device developer Relievant completes $30mm Series D financing
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice